

North America Mid-Size Pharmaceutical Market Size and Forecast (2021 - 2034), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription and Over-the-Counter), Drug Development Type (In-House and Outsource), Drug Designation Type (Orphan Drugs and Non-Orphan Drugs), Formulation (Tablets and Capsules, Injectables, Topical, and Others), Indication (Cardiovascular Diseases, Pain Management, Respiratory Diseases, Diabetes, Oncology, Infectious Diseases, Neurology, Immunology, Ophthalmology, Autoimmune, and Others)

<https://marketpublishers.com/r/NDE845DBBF9EEN.html>

Date: June 2026

Pages: 172

Price: US\$ 3,450.00 (Single User License)

ID: NDE845DBBF9EEN

Abstracts

According to our new research study on “North America Mid-Size Pharmaceutical Market Forecast to 2034 –Global Analysis – by Type, Intended Parents, Journey Type, Technology, and Geography,” the market is anticipated to grow from US\$ 330.90 billion in 2025 and is projected to reach US\$ 562.94 billion by 2034; it is expected to register a CAGR of 6.3% during 2026–2034. The North America Mid-Size Pharmaceutical market growth is attributed to advancement of biotechnology and precision medicine increased healthcare spending and better insurance coverage.

The Pharmaceutical market definition encompasses the industries which are engaged in activities such as research, development, manufacturing, and distribution of drugs that are used in treatment of diseases. The key participants in the pharmaceutical market

are pharmaceutical producers, biotechnology companies, contract drug manufacturers, laboratories, and others who participate in the process of researching, developing, manufacturing, and distributing drugs. This market serves the interests of people of all ages and in the field of treatment for many types of diseases. These include, but are not limited to, chronic diseases, infectious diseases, cancer-related diseases, rare diseases, and many others. The development of the pharmaceutical market is due to such factors as prevalence of diseases, aging of the population, advances in biotechnology, increasing expenditure in health care, etc.

The pharmaceutical market in North America can be divided into the US, Canada, and Mexico. North America has emerged as one of the dominant players within the pharmaceutical industry. It has strong regulatory mechanisms, good healthcare infrastructure, and high levels of investment in research and development. This pharmaceutical market boasts an extensive network of pharmaceutical companies, biotech companies, and contract development and manufacturing organizations (CDMOs) that engage in drug discovery, development, and commercialization at a mass scale. The US remains dominant in this market owing to its strong R&D facilities, presence of leading global pharmaceutical companies, and regulatory frameworks supporting drug approvals. Canada and Mexico are also playing their part through improved healthcare accessibility and increased production capacity. In 2023, North America had a considerable share in global drug development activities.

There exists a philanthropic approach to regulating the pharmaceutical industry in Canada in line with ethical practice guidelines. The regulation process in Canada is driven by policies developed in the government to ensure safe practices within the sector. Healthcare innovation in Canada is regulated with respect to adherence to regulatory requirements in addition to reforms at the provincial level to facilitate clear clinical, research, and healthcare processes. The Mexican market involves a mixture of regulation and regional policymaking with efforts to ensure regulatory harmony in order to facilitate increased access to cutting-edge medicine. Divergent regulatory periods may be responsible for disparities in adoption within each market. Increasing policy reforms aimed at improving healthcare governance in North America are likely to facilitate the adoption of drugs domestically and increase market opportunities.

Legal and regulatory conflicts related to the pharmaceutical and healthcare sector have been rising in frequency between different jurisdictions and therefore, there is a growing need for more harmonization within the field in Europe and internationally. Legal frameworks and regulatory measures developed in partnership with the European Union will help increase regulation coherence in addition to promoting consistent healthcare

rights recognition in EU member states. In the international arena, bodies like the Hague Conference on Private International Law are Also, some nations are reforming their legislation in order to achieve more harmonization and increase healthcare service accessibility. Specifically, the country of Denmark has adopted new legislation designed to promote greater oversight within the sector. The United Kingdom is proposing legislation that is geared towards simplifying access and other legal matters relating to healthcare services. Meanwhile, the United States has revised the Uniform Parentage Act, which has helped improve legal uniformity among US states. All of the reforms will go a long way in fostering more coherent regulation and growth in the sector.

Key insights and analysis of the pharmaceutical market are derived from leading global healthcare, regulatory, and research organizations. These include the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), along with industry associations and clinical research databases. Additional inputs are taken from peer-reviewed journals, company financial reports, and healthcare analytics platforms. These sources collectively provide reliable data on drug development trends, regulatory frameworks, clinical trials, and market performance. Together, they help ensure accurate evaluation of the pharmaceutical market, supporting insights into innovation, policy developments, and global industry growth patterns.

Reason to buy

Saves and reduces time required for identifying the market growth, size, leading players, and segments in the North America Mid-Size Pharmaceutical market.

Highlights key business priorities to assist companies in realigning their business strategies

Emphasizes key findings and recommendations that uncover emerging industry trends in the North America Mid-Size Pharmaceutical market, enabling stakeholders across the value chain to craft effective long-term strategies

Develop/modify business expansion plans by analyzing substantial growth prospects in mature and emerging markets

Scrutinizes in-depth North America Mid-Size Pharmaceutical market trends, along with factors driving the market, as well as those hindering it

Enhances the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Contents

1. EXECUTIVE SUMMARY

1.1 Analyst Market Outlook

2. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 LANDSCAPE

2.1 Overview

2.2 Value Chain Analysis

2.2.1 Raw Materials/Components

2.2.2 Manufacturing Process/Technology

2.2.3 Distribution Landscape

2.2.4 End User

2.2.5 Level of Integration

2.3 Supply Chain Analysis

2.3.1 List of Manufacturers/Suppliers

2.3.2 List of Potential Customers (Upto 50)

2.4 Porter`s Five Force Analysis

2.4.1 Competitive Rivalry – High

2.4.2 Bargaining Power of Suppliers – Moderate to High

2.4.3 Bargaining Power of Buyers – High

2.4.4 Threat of Substitutes – Moderate

2.4.5 Threat of New Entrants – Moderate to Low

2.5 PEST Analysis

2.6 Impact of Artificial Intelligence (AI)

2.7 Product or Technology Roadmap

2.8 Sustainability and ESG Trends

2.9 Patent Analysis

2.10 Regulatory Framework

2.11 Pipeline Analysis

2.12 Prevalence of Key Indications, North America

3. COMPETITIVE LANDSCAPE

3.1 Company Benchmarking by Key Players

3.2 Market Share Analysis, 2025 – By Key Players

3.3 Market Concentration

4. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 – KEY INDUSTRY DYNAMICS

4.1 Market Drivers

4.1.1 Rising Prevalence of Chronic Diseases

4.1.2 Expansion of Rare Disease Diagnosis and Orphan Drug Development Across North America

4.1.3 Accelerated Drug Approvals and Rising Pharmaceutical Innovation Ecosystem in North America

4.2 Market Restraints

4.2.1 Stringent Regulatory Compliance and Increasing Drug Approval Complexity

4.2.2 High Cost of Drug Development and Clinical Trial Execution

4.2.3 Supply Chain Disruptions and Manufacturing Dependency on Third Parties

4.3 Market Opportunities

4.3.1 Expansion of Biosimilars and Cost-Effective Biologics in North America

4.3.2 Expansion of Domestic Manufacturing and CDMO Outsourcing Ecosystem

4.3.3 Expansion of Oncology Innovation and Precision Medicine in North America

4.4 Future Trends

4.4.1 Expansion of Precision Medicine and Biomarker-Driven Therapeutics in North America

4.4.2 Expansion of Outsourced Research and Development and Strategic CRO/CDMO Partnerships

4.4.3 Surging Dominance of Specialty and High-Value Therapeutic Drug Classes

4.5 Impact of Drivers and Restraints

5. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 – REGION MARKET ANALYSIS

5.1 North America Mid-Size Pharmaceutical Market to 2034

5.2 Overview

5.3 North America Mid-Size Pharmaceutical Market to 2034 Revenue (US\$ Billion), 2021–2034

5.4 North America Mid-Size Pharmaceutical Market to 2034 Forecast and Analysis

6. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 REVENUE ANALYSIS – TYPE

6.1 North America Mid-Size Pharmaceutical Market to 2034 Forecasts and Analysis by

Type

6.1.1 Prescription

6.1.1.1 Overview

6.1.1.2 Prescription: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

6.1.2 Over-the-Counter

6.1.2.1 Overview

6.1.2.2 Over-the-Counter: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

7. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 REVENUE ANALYSIS – DRUG DEVELOPMENT TYPE

7.1 North America Mid-Size Pharmaceutical Market to 2034 Forecasts and Analysis by Drug Development Type

7.1.1 In-House

7.1.1.1 Overview

7.1.1.2 In-House: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

7.1.2 Outsource

7.1.2.1 Overview

7.1.2.2 Outsource: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

8. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 REVENUE ANALYSIS – DRUG DESIGNATION TYPE

8.1 North America Mid-Size Pharmaceutical Market to 2034 Forecasts and Analysis by Drug Designation Type

8.1.1 Orphan Drugs

8.1.1.1 Overview

8.1.1.2 Orphan Drugs: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

8.1.2 Non-Orphan Drugs

8.1.2.1 Overview

8.1.2.2 Non-Orphan Drugs: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

9. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 REVENUE

ANALYSIS – FORMULATION

9.1 North America Mid-Size Pharmaceutical Market to 2034 Forecasts and Analysis by Formulation

9.1.1 Tablets and Capsules

9.1.1.1 Overview

9.1.1.2 Tablets and Capsules: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

9.1.2 Injectables

9.1.2.1 Overview

9.1.2.2 Injectables: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

9.1.3 Topical

9.1.3.1 Overview

9.1.3.2 Topical: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

9.1.4 Others

9.1.4.1 Overview

9.1.4.2 Others: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

10. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 REVENUE ANALYSIS – INDICATION

10.1 North America Mid-Size Pharmaceutical Market to 2034 Forecasts and Analysis by Indication

10.1.1 Cardiovascular Diseases

10.1.1.1 Overview

10.1.1.2 Cardiovascular Diseases: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

10.1.2 Pain Management

10.1.2.1 Overview

10.1.2.2 Pain Management: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

10.1.3 Respiratory Diseases

10.1.3.1 Overview

10.1.3.2 Respiratory Diseases: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2034 (US\$ Billion)

10.1.4 Diabetes

10.1.4.1 Overview

10.1.4.2 Diabetes: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.5 Oncology

10.1.5.1 Overview

10.1.5.2 Oncology: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.6 Infectious Diseases

10.1.6.1 Overview

10.1.6.2 Infectious Diseases: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.7 Neurology

10.1.7.1 Overview

10.1.7.2 Neurology: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.8 Immunology

10.1.8.1 Overview

10.1.8.2 Immunology: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.9 Ophthalmology

10.1.9.1 Overview

10.1.9.2 Ophthalmology: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.10 Autoimmune

10.1.10.1 Overview

10.1.10.2 Autoimmune: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

10.1.11 Others

10.1.11.1 Overview

10.1.11.2 Others: North America Mid-Size Pharmaceutical Market to 2034 –
Revenue, 2021–2034 (US\$ Billion)

11. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 – COUNTRY ANALYSIS

11.1 North America Mid-Size Pharmaceutical Market to 2034 Breakdown by Countries

11.1.1 United States Market

11.1.1.1 United States: North America Mid-Size Pharmaceutical Market to 2034
Revenue and Forecasts, 2021–2034 (US\$ Billion)

11.1.1.2 United States: North America Mid-Size Pharmaceutical Market to 2034 – By Segmentation

11.1.1.2.1 Type

11.1.1.2.2 Drug Development Type

11.1.1.2.3 Drug Designation Type

11.1.1.2.4 Formulation

11.1.1.2.5 Indication

11.1.2 Canada Market

11.1.2.1 Canada: North America Mid-Size Pharmaceutical Market to 2034 Revenue and Forecasts, 2021–2034 (US\$ Billion)

11.1.2.2 Canada: North America Mid-Size Pharmaceutical Market to 2034 – By Segmentation

11.1.2.2.1 Type

11.1.2.2.2 Drug Development Type

11.1.2.2.3 Drug Designation Type

11.1.2.2.4 Formulation

11.1.2.2.5 Indication

11.1.3 Mexico Market

11.1.3.1 Mexico: North America Mid-Size Pharmaceutical Market to 2034 Revenue and Forecasts, 2021–2034 (US\$ Billion)

11.1.3.2 Mexico: North America Mid-Size Pharmaceutical Market to 2034 – By Segmentation

11.1.3.2.1 Type

11.1.3.2.2 Drug Development Type

11.1.3.2.3 Drug Designation Type

11.1.3.2.4 Formulation

11.1.3.2.5 Indication

12. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 INDUSTRY LANDSCAPE

13. NORTH AMERICA MID-SIZE PHARMACEUTICAL MARKET TO 2034 – KEY COMPANY PROFILES

13.1 Regeneron Pharmaceuticals Inc

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Alexion Pharmaceuticals Inc
 - 13.2.1 Key Facts
 - 13.2.2 Business Description
 - 13.2.3 Products and Services
 - 13.2.4 Financial Overview
 - 13.2.5 SWOT Analysis
 - 13.2.6 Key Developments
- 13.3 Bausch Health Companies Inc
 - 13.3.1 Key Facts
 - 13.3.2 Business Description
 - 13.3.3 Products and Services
 - 13.3.4 Financial Overview
 - 13.3.5 SWOT Analysis
 - 13.3.6 Key Developments
- 13.4 Mallinckrodt Plc
 - 13.4.1 Key Facts
 - 13.4.2 Business Description
 - 13.4.3 Products and Services
 - 13.4.4 Financial Overview
 - 13.4.5 SWOT Analysis
 - 13.4.6 Key Developments
- 13.5 Corcept Therapeutics Inc
 - 13.5.1 Key Facts
 - 13.5.2 Business Description
 - 13.5.3 Products and Services
 - 13.5.4 Financial Overview
 - 13.5.5 SWOT Analysis
 - 13.5.6 Key Developments
- 13.6 BioMarin Pharmaceutical Inc.
 - 13.6.1 Key Facts
 - 13.6.2 Business Description
 - 13.6.3 Products and Services
 - 13.6.4 Financial Overview
 - 13.6.5 SWOT Analysis
 - 13.6.6 Key Developments
- 13.7 Amgen Inc
 - 13.7.1 Key Facts

- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Endo International plc
 - 13.8.1 Key Facts
 - 13.8.2 Business Description
 - 13.8.3 Products and Services
 - 13.8.4 Financial Overview
 - 13.8.5 SWOT Analysis
 - 13.8.6 Key Developments
- 13.9 Jazz Pharmaceuticals Plc
 - 13.9.1 Key Facts
 - 13.9.2 Business Description
 - 13.9.3 Products and Services
 - 13.9.4 Financial Overview
 - 13.9.5 SWOT Analysis
 - 13.9.6 Key Developments
- 13.10 Incyte Corp
 - 13.10.1 Key Facts
 - 13.10.2 Business Description
 - 13.10.3 Products and Services
 - 13.10.4 Financial Overview
 - 13.10.5 SWOT Analysis
 - 13.10.6 Key Developments

14. LIST OF ADDITIONAL COMPANIES ANALYZED

- 14.1 List of Additional Companies Analyzed

15. APPENDIX

- 15.1 Glossary
- 15.2 Research Methodology and Approach
 - 15.2.1 Secondary Research
 - 15.2.2 Primary Research
 - 15.2.3 Market Estimation Approach
 - 15.2.3.1 Supply Side Analysis

- 15.2.3.2 Demand Side Analysis
- 15.2.4 Research Assumptions and Limitations
- 15.2.5 Currency Conversion
- 15.3 About The Insight Partners
- 15.4 Market Intelligence Cloud

List Of Tables

LIST OF TABLES

Table 1. List of Patents and Description

Table 2. List of Regulatory Bodies and Organizations

Table 3. Ease of Doing Business: Key Country Rankings

Table 4. Pipeline Analysis

Table 5. Prevalence of Key Indications, North America

Table 6. Market Share Analysis, 2025 – By Key Players

Table 7. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion)

Table 8. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion)

Table 9. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Type

Table 10. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Type

Table 11. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Development Type

Table 12. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Development Type

Table 13. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Designation Type

Table 14. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Designation Type

Table 15. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Formulation

Table 16. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Formulation

Table 17. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Indication

Table 18. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Indication

Table 19. North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Country

Table 20. North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Country

Table 21. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Type

Table 22. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Type

Table 23. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Development Type

Table 24. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Development Type

Table 25. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Designation Type

Table 26. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Designation Type

Table 27. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Formulation

Table 28. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Formulation

Table 29. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Indication

Table 30. United States: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Indication

Table 31. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Type

Table 32. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Type

Table 33. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Development Type

Table 34. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Development Type

Table 35. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Designation Type

Table 36. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Designation Type

Table 37. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Formulation

Table 38. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Formulation

Table 39. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Indication

Table 40. Canada: North America Mid-Size Pharmaceutical Market to 2034 – Revenue

Forecast, 2026–2034 (US\$ Billion) – by Indication

Table 41. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Type

Table 42. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Type

Table 43. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Development Type

Table 44. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Development Type

Table 45. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Drug Designation Type

Table 46. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Drug Designation Type

Table 47. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Formulation

Table 48. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Formulation

Table 49. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue, 2021–2025 (US\$ Billion) – by Indication

Table 50. Mexico: North America Mid-Size Pharmaceutical Market to 2034 – Revenue Forecast, 2026–2034 (US\$ Billion) – by Indication

Table 51. List of Additional Companies Analyzed

Table 52. Glossary – North America Mid-Size Pharmaceutical Market to 2034

List Of Figures

LIST OF FIGURES

Figure 1. North America Mid-Size Pharmaceutical Market to 2034 Segmentation.

Figure 2. North America Mid-Size Pharmaceutical Market to 2034 – Value Chain Analysis

Figure 3. Porter's Five Forces Analysis

Figure 4. Pest Analysis

Figure 5. North America Mid-Size Pharmaceutical Market to 2034 – Key Industry Dynamics

Figure 6. Impact Analysis of Drivers and Restraints

Figure 7. North America Mid-Size Pharmaceutical Market to 2034 Revenue (US\$ Billion), 2021–2034

Figure 8. North America Mid-Size Pharmaceutical Market to 2034 Share (%) – by Type (2025 and 2034)

Figure 9. Prescription: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 10. Over-the-Counter: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 11. North America Mid-Size Pharmaceutical Market to 2034 Share (%) – by Drug Development Type (2025 and 2034)

Figure 12. In-House: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 13. Outsource: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 14. North America Mid-Size Pharmaceutical Market to 2034 Share (%) – by Drug Designation Type (2025 and 2034)

Figure 15. Orphan Drugs: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 16. Non-Orphan Drugs: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 17. North America Mid-Size Pharmaceutical Market to 2034 Share (%) – by Formulation (2025 and 2034)

Figure 18. Tablets and Capsules: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 19. Injectables: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 20. Topical: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 21. Others: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 22. North America Mid-Size Pharmaceutical Market to 2034 Share (%) – by Indication (2025 and 2034)

Figure 23. Cardiovascular Diseases: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 24. Pain Management: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 25. Respiratory Diseases: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 26. Diabetes: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 27. Oncology: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 28. Infectious Diseases: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 29. Neurology: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 30. Immunology: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 31. Ophthalmology: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 32. Autoimmune: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 33. Others: North America Mid-Size Pharmaceutical Market to 2034 – Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 34. North America Mid-Size Pharmaceutical Market to 2034 Breakdown by Key Countries, 2025 and 2034 (%)

Figure 35. United States: North America Mid-Size Pharmaceutical Market to 2034 Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 36. Canada: North America Mid-Size Pharmaceutical Market to 2034 Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 37. Mexico: North America Mid-Size Pharmaceutical Market to 2034 Revenue and Forecasts, 2021–2034 (US\$ Billion)

Figure 38. Bottom–Up Approach and Top–Down Approach

I would like to order

Product name: North America Mid-Size Pharmaceutical Market Size and Forecast (2021 - 2034), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription and Over-the-Counter), Drug Development Type (In-House and Outsource), Drug Designation Type (Orphan Drugs and Non-Orphan Drugs), Formulation (Tablets and Capsules, Injectables, Topical, and Others), Indication (Cardiovascular Diseases, Pain Management, Respiratory Diseases, Diabetes, Oncology, Infectious Diseases, Neurology, Immunology, Ophthalmology, Autoimmune, and Others)

Product link: <https://marketpublishers.com/r/NDE845DBBF9EEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NDE845DBBF9EEN.html>